Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare
Nicole Gormley, Lola A. Fashoyin‐Aje, Trevan Locke, Joseph M. Unger, Richard F. Little, Ajay K. Nooka, Khalid Mezzi, Mihaela Popa-McKiver, Rachel Kobos, Yelak Biru, Tiffany H. Williams, Kenneth C. Anderson
Abstract
African Americans are at higher risk of multiple myeloma (MM) yet underrepresented in clinical trials and reap less benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, providers, patients, industry partners and regulators at the FDA-AACR workshop developed recommendations to all stakeholders. The outlined principles offer a roadmap to addressing disparities broadly in clinical trials.
Topics & Concepts
Clinical trialHealth equityEquity (law)Multiple myelomaMedicineHealth careClinical researchFamily medicinePolitical scienceNursingInternal medicinePublic healthLawMultiple Myeloma Research and TreatmentsHIV/AIDS drug development and treatmentProtein Degradation and Inhibitors